- Home
- SEVN vs VXRT Comparison
SEVN vs VXRT Comparison
Compare SEVN & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- VXRT
- Stock Information
- Founded
- SEVN 1986
- VXRT N/A
- Country
- SEVN United States
- VXRT United States
- Employees
- SEVN N/A
- VXRT N/A
- Industry
- SEVN Real Estate Investment Trusts
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEVN Real Estate
- VXRT Health Care
- Exchange
- SEVN Nasdaq
- VXRT Nasdaq
- Market Cap
- SEVN 209.5M
- VXRT 200.3M
- IPO Year
- SEVN N/A
- VXRT N/A
- Fundamental
- Price
- SEVN $14.18
- VXRT $0.81
- Analyst Decision
- SEVN Strong Buy
- VXRT Strong Buy
- Analyst Count
- SEVN 3
- VXRT 2
- Target Price
- SEVN $14.50
- VXRT $3.00
- AVG Volume (30 Days)
- SEVN 71.1K
- VXRT 1.1M
- Earning Date
- SEVN 10-28-2024
- VXRT 10-31-2024
- Dividend Yield
- SEVN 9.78%
- VXRT N/A
- EPS Growth
- SEVN N/A
- VXRT N/A
- EPS
- SEVN 1.55
- VXRT N/A
- Revenue
- SEVN $33,543,000.00
- VXRT $13,928,000.00
- Revenue This Year
- SEVN N/A
- VXRT $67.68
- Revenue Next Year
- SEVN N/A
- VXRT N/A
- P/E Ratio
- SEVN $9.22
- VXRT N/A
- Revenue Growth
- SEVN 11.31
- VXRT 577.76
- 52 Week Low
- SEVN $10.14
- VXRT $0.52
- 52 Week High
- SEVN $14.48
- VXRT $1.54
- Technical
- Relative Strength Index (RSI)
- SEVN 58.48
- VXRT 48.09
- Support Level
- SEVN $13.85
- VXRT $0.77
- Resistance Level
- SEVN $14.48
- VXRT $0.83
- Average True Range (ATR)
- SEVN 0.24
- VXRT 0.05
- MACD
- SEVN 0.03
- VXRT -0.00
- Stochastic Oscillator
- SEVN 66.29
- VXRT 32.00
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.